The Lapchak Laboratory is focused on stroke translational therapy development. Paul A. Lapchak, PhD, FAHA, is directing translational stroke research funded by the pharmaceutical and biotechnology industry and gift donations.
Annually, there are 15 million stroke victims worldwide. The goal of this research is to develop new therapeutic approaches to treat acute ischemic and hemorrhagic stroke, using an embolic stroke model to develop strategies to treat stroke patients with diabetes, hypercholesterolemia and hypertension.
There is a critical medical need for new therapeutic strategies to treat acute ischemic stroke (AIS) and hemorrhagic stroke to reduce mortality and improve the quality of life for stroke victims. Current statistics indicate that stroke is the fifth leading cause of death and the leading cause of adult disability in the United States, with upward of 795,000 victims annually suffering a new or recurrent stroke, despite improved diet and control of diabetes, hypertension and hypercholesterolemia. Currently, the only Food and Drug Administration (FDA) approved treatment for stroke is the thrombolytic tissue plasminogen activator (tPA), administered within three hours of a stroke. Although thrombolysis is now widely accepted as a standard of care for AIS, only a minority (six-ten percent) of AIS patients are treated with tPA in the United States.
However, tPA itself is not neuroprotective and does not prevent all clinical disabilities resulting from embolic strokes. Because there is still a real need for effective neuroprotective treatments to attenuate neuronal loss or promote recovery of function, we have focused on identifying and developing novel drugs and devices that can be effective when administered after an ischemic event